Does not affect blood glucose or insulin levels, avoiding the potential metabolic risks associated with hGH therapy
Keep a simple log for the first 4 to 6 weeks tracking: Injection day and time
A full medical consultation is essential to determine if this therapy is suitable for you
Cross-trial scans favor tirzepatide: semaglutide measured about 62:38 fat-to-lean loss versus roughly 75:25 for tirzepatide. The scan overstates muscle loss, however, because lean mass includes water and organs
Outcome Over the following weeks most people notice GI comfort improving first, less bloating and digestive discomfort (weeks 12), then more consistent digestion and less food sensitivity (weeks 24), then broader recovery benefits and a gut that feels stable and resilient (weeks 412)
You will need to be careful to avoid interactions with other drugs, particularly those that treat various digestive issues